GUD vs. TLRY, CRON, THCX, CPH, ACB, WEED, FIRE, OGI, EPI, and ICC
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Knight Therapeutics vs.
Knight Therapeutics (TSE:GUD) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
12.6% of Knight Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Tilray Brands shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Knight Therapeutics has higher earnings, but lower revenue than Tilray Brands. Knight Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Knight Therapeutics currently has a consensus target price of C$7.08, suggesting a potential upside of 27.17%. Tilray Brands has a consensus target price of C$2.95, suggesting a potential upside of 70.52%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Knight Therapeutics.
Knight Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.
In the previous week, Tilray Brands had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.31 beat Knight Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.
Knight Therapeutics received 112 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 73.68% of users gave Knight Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote.
Knight Therapeutics has a net margin of -6.28% compared to Tilray Brands' net margin of -31.05%. Knight Therapeutics' return on equity of -2.70% beat Tilray Brands' return on equity.
Summary
Knight Therapeutics beats Tilray Brands on 12 of the 19 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
This page (TSE:GUD) was last updated on 1/21/2025 by MarketBeat.com Staff
